Clinical and radiological outcomes after intracranial atherosclerotic stroke: A comprehensive approach comparing stroke subtypes

Cerebrovascular Diseases

Volumn 31, Issue 5, 2011, Pages 427-434

  Kim, Suk Jae ^a   Ryoo, Sookyoung ^a   Kim, Gyeong Moon ^a   Chung, Chin Sang ^a   Lee, Kwang Ho ^a   Bang, Oh Young ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Atherosclerosis; Magnetic resonance imaging; Perfusion; Stroke evolution; Stroke, ischemic

Indexed keywords

FIBRINOLYTIC AGENT; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ADULT; AGED; ARTICLE; BARTHEL INDEX; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN MAPPING; BRAIN PERFUSION; CARDIOEMBOLIC STROKE; CONTROLLED STUDY; CRYPTOGENIC EMBOLIC STROKE; DIFFUSION WEIGHTED IMAGING; EXTRACRANIAL LARGE ARTERY ATHEROSCLEROTIC STROKE; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTRACRANIAL LARGE ARTERY ATHEROSCLEROTIC STROKE; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RANKIN SCALE; RECANALIZATION; RECURRENCE RISK; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; CEREBRAL ANGIOGRAPHY; COLLATERAL CIRCULATION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL EMBOLISM; LOGISTIC MODELS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951851984     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323610     Document Type: Article

References (25)

1. Caplan LR, Gorelick PB, Hier DB: Race, sex and occlusive cerebrovascular disease: a review.Stroke 1986; 17: 648-655. (Pubitemid 16066533)
2. Gorelick PB: Distribution of atherosclerotic cerebrovascular lesions. Effects of age, race, and sex. Stroke 1993; 24:I16-I19, discussion I20-I21. (Pubitemid 23350048)
3. Gorelick PB, Wong KS, Bae HJ, Pandey DK: Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke 2008; 39: 2396-2399.
4. Kieffer SA, Takeya Y, Resch JA, Amplatz K: Racial differences in cerebrovascular disease.Angiographic evaluation of Japanese and American populations. Am J Roentgenol Radium Ther Nucl Med 1967; 101: 94-99.
5. Liu HM, Tu YK, Yip PK, Su CT: Evaluationof intracranial and extracranial carotid steno-occlusive diseases in Taiwan Chinese patientswith MR angiography: preliminaryexperience. Stroke 1996; 27: 650-653.
6. Wong KS, Huang YN, Gao S, Lam WW, Chan YL, Kay R: Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998; 50: 812-813.
7. Kim SJ, Seok JM, Bang OY, Kim GM, Kim KH, Jeon P, Chung CS, Lee KH, Alger JR, Lie beskind DS: MR mismatch profiles in patients with intracranial atherosclerotic stroke: a comprehensive approach comparing stroke subtypes. J Cereb Blood Flow Metab 2009; 29: 1138-1145.
8. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ: An evidencebased causative classification system for acute ischemic stroke. Ann Neurol 2005; 58: 688-697. (Pubitemid 41552544)
9. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR: High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. 1. Mathematical approach and statistical analysis.Magn Reson Med 1996; 36: 715-725. (Pubitemid 26376710)
10. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D: Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003; 34:e109-e137.
11. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
12. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
13. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European- Australasian Acute Stroke Study Investigators.Lancet 1998; 352: 1245-1251. (Pubitemid 28470336)
14. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-2026.
15. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRIbased 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.Stroke 2005; 36: 66-73. (Pubitemid 40054177)
16. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP: Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.Ann Neurol 2006; 60: 508-517. (Pubitemid 44871793)
17. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-1231. (Pubitemid 43731867)
18. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM: Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7: 299-309.
19. Bang OY, Saver JL, Buck BH, Alger JR, Starkman S, Ovbiagele B, Kim D, Jahan R, Duckwiler GR, Yoon SR, Vinuela F, Liebeskind DS: Impact of collateral flow on tissue fate in acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2008; 79: 625-629. (Pubitemid 351829431)
20. Bang OY, Kim GM, Chung CS, Kim SJ, Kim KH, Jeon P, Saver JL, Liebeskind DS, Lee KH: Differential pathophysiological mechanisms of stroke evolution between new lesions and lesion growth: perfusion-weighted imaging study. Cerebrovasc Dis 2010; 29: 328-335.
21. Kang DW, Kwon SU, Yoo SH, Kwon KY, Choi CG, Kim SJ, Koh JY, Kim JS: Early recurrent ischemic lesions on diffusion-weighted imaging in symptomatic intracranial atherosclerosis.Arch Neurol 2007; 64: 50-54. (Pubitemid 46072423)
22. Shin DH, Lee PH, Bang OY: Mechanisms of recurrence in subtypes of ischemic stroke: a hospital-based follow-up study. Arch Neurol 2005; 62: 1232-1237.
23. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316.
24. Thijs VN, Albers GW: Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000; 55: 490-497. (Pubitemid 30647243)
25. Davis SM, Donnan GA, Butcher KS, Parsons M: Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol 2005; 18: 47-52. (Pubitemid 40270265)